Englewood Health Earns Reaccreditation for Transcatheter Valve Program from the American College of Cardiology

Bergen County’s first hospital to earn this recognition continues to set the standard in minimally invasive heart valve care

March 26, 2025 — Englewood Health has been recognized by the American College of Cardiology (ACC) with reaccreditation of its Transcatheter Valve Certification, reinforcing its commitment to excellence in structural heart care. Originally earning this prestigious distinction in 2022 as the first hospital in Bergen County to receive the honor, Englewood Health remains at the forefront of minimally invasive heart valve treatments.

“We are seeing more patients turn to Englewood Health for advanced valve treatments because of our expertise, minimally invasive approach, and commitment to personalized care,” said Ramin Hastings, MD, medical director of the Structural Heart and Valve Program at Englewood Health. “As one of the most experienced centers in the region, we offer a comprehensive range of transcatheter valve therapies, giving patients access to more options, faster recovery times, and the latest innovations.”

Englewood Health’s Structural Heart and Valve Program offers a range of minimally invasive transcatheter valve therapies, including: 

• Transcatheter Aortic Valve Replacement (TAVR): A minimally invasive procedure that replaces a narrowed aortic valve to treat aortic stenosis. Englewood Health has performed 1,700+ TAVR procedures, offering patients a safer alternative to open-heart surgery.
• Transcatheter Edge-to-Edge Repair (TEER): A catheter-based technique that clips the mitral or tricuspid valve leaflets to reduce regurgitation. Englewood Health offers MitraClip and PASCAL for mitral regurgitation, and TriClip for tricuspid regurgitation.
• Transcatheter Tricuspid Valve Replacement (TTVR): A minimally invasive procedure to replace a diseased tricuspid valve. Englewood Health is among the first in New Jersey to offer EVOQUE, the first FDA-approved transcatheter valve replacement for tricuspid regurgitation.

The recent ACC reaccreditation follows a rigorous evaluation process, assessing the program’s ability to meet high standards for multidisciplinary teamwork, formalized training, shared decision-making, and high-quality performance as measured in national registries.

“This reaccreditation underscores our dedication to delivering outstanding structural heart care with exceptional outcomes,” said Joseph De Gregorio, MD, executive director of cardiovascular services at Englewood Health. “Our multidisciplinary team of interventional cardiologists, cardiothoracic surgeons, and specialized clinical staff work together to provide cutting-edge treatments while ensuring the highest level of safety and quality for every patient.”